Anti-EIF2S1 antibody [EIF2S1A2B8]
Be the first to review this product! Submit a review
|
(2 Publications )
- ICC/IF
Unknown
Immunocytochemistry/ Immunofluorescence - Anti-EIF2S1 antibody [EIF2S1A2B8] (AB50733)
ab50733 at 1/1 dilution staining human EIF2S1 in HeLa Cells by Immunocytochemistry. A 1/200 dilution of Alexa Fluor 488 anti-mouse IgG is used as a secondary.
- WB
Unknown
Western blot - Anti-EIF2S1 antibody [EIF2S1A2B8] (AB50733)
All lanes:
Western blot - Anti-EIF2S1 antibody [EIF2S1A2B8] (ab50733) at 1/50 dilution
All lanes:
NIH3T3 whole cell lysate at 50 µg
Secondary
All lanes:
anti-Mouse IgG at 1/2500 dilution
Predicted band size: 36 kDa
Observed band size: 33 kDa
true
- WB
CiteAb
Western blot - Anti-EIF2S1 antibody [EIF2S1A2B8] (AB50733)
EIF2S1 western blot using anti-EIF2S1 antibody [EIF2S1A2B8] ab50733. Publication image and figure legend from Yu, Y., Pierciey, F. J., et al., 2013, PLoS Pathog, PubMed 23592989.
ab50733 was used in this publication in western blot. This may not be the same as the application(s) guaranteed by Abcam. For a full list of applications guaranteed by Abcam for ab50733 please see the product overview.
Introduction of Insig1-Myc inhibits HCMV growth and lipid synthesis in HCMV-infected cells.(A) The effect of PERK depletion on Insig1 levels and eIF2α phosphorylation. Human fibroblasts stably transfected with pCMV-Insig1-Myc were treated with shGFP or shPERK for three days, followed by one day serum starvation and then either mock- or HCMV-infected. Whole cell extracts were prepared for Western analysis at 48 hpi. Extracts were probed with anti-PERK, anti-Myc, anti-phospho-eIF2α, anti-total eIF2α and anti-actin. Two exposures of the Insig1-myc analysis are provided. S, short exposure; L, long exposure. (B) Introduction of exogenous Insig1-Myc inhibits HCMV growth. HF cells were treated with shGFP or shPERK for two days subsequent to transient transfection with pCMV-Insig1-Myc or the vector control (pCDNA3), then the cells were serum-starved for two hours and infected with HCMV. Viruses were harvested for titration at 72 hpi. See text for details. (C) Lipid synthesis in Insig1-Myc expressing HF cells. HF cells were treated as described in (B) prior to mock or HCMV infection. Total lipid synthesis was measured at 48 hpi.
false
Reactivity data
Properties and storage information
Form
Purification technique
Purification notes
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
EIF2α acts as a regulatory component of the eIF2 complex which is central to initiating translation in eukaryotic cells. Phosphorylation of eIF2α leads to inhibition of the exchange of GDP to GTP on eIF2 effectively reducing global protein synthesis while allowing the translation of specific mRNAs involved in stress responses. The eIF2α forms part of the eIF2 complex working closely with other subunits to exert its regulatory functions.
Pathways
EIF2α is involved in the integrated stress response (ISR) and other protein synthesis pathways. The phosphorylation state of eIF2α is important in ISR linking it to proteins such as PERK and GCN2 which respond to various stress signals. Phospho-eIF2α plays a significant role in modulating the translation response to cellular stress ensuring cells can adapt or initiate apoptosis depending on the conditions.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Alternative Names
Publications (2)
Recent publications for all applications. Explore the full list and refine your search
Scientific reports 10:386 PubMed31941974
2020
Applications
Unspecified application
Species
Unspecified reactive species
PLoS pathogens 9:e1003266 PubMed23592989
2013
Applications
WB
Species
Human
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com